UBS Group’s enVVeno Medical Corporation Warrants NVNOW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-4,275
| Closed | -$86 | – | 11162 |
|
|
2022
Q4 | $86 | Sell |
4,275
-872
| -17% | -$87 | ﹤0.01% | 10420 |
|
|
2022
Q3 | $1K | Buy |
5,147
+612
| +13% | +$98 | ﹤0.01% | 10181 |
|
|
2022
Q2 | $1K | Hold |
4,535
| – | – | ﹤0.01% | 10111 |
|
|
2022
Q1 | $1K | Buy |
4,535
+1,127
| +33% | +$267 | ﹤0.01% | 10046 |
|
|
2021
Q4 | $1K | Buy |
3,408
+3,216
| +1,675% | +$1.22K | ﹤0.01% | 10116 |
|
|
2021
Q3 | $0 | Sell |
192
-12,847
| -99% | -$4.21K | ﹤0.01% | 10386 |
|
|
2021
Q2 | $3K | Sell |
13,039
-11,513
| -47% | -$2.93K | ﹤0.01% | 8874 |
|
|
2021
Q1 | $8K | Sell |
24,552
-62,814
| -72% | -$20.8K | ﹤0.01% | 8113 |
|
|
2020
Q4 | $28K | Buy |
87,366
+82,726
| +1,783% | +$11.1K | ﹤0.01% | 6707 |
|
|
2020
Q3 | $0 | Buy |
4,640
+3,340
| +257% | +$397 | ﹤0.01% | 8590 |
|
|
2020
Q2 | $0 | Buy |
+1,300
| New | +$171 | ﹤0.01% | 8506 |
|
|
2020
Q1 | – | Sell |
-7,784
| Closed | -$1K | – | 8572 |
|
|
2019
Q4 | $1K | Hold |
7,784
| – | – | ﹤0.01% | 8008 |
|
|
2019
Q3 | $1K | Sell |
7,784
-16
| -0.2% | -$3 | ﹤0.01% | 7874 |
|
|
2019
Q2 | $2K | Hold |
7,800
| – | – | ﹤0.01% | 7656 |
|
|
2019
Q1 | $3K | Buy |
7,800
+1,600
| +26% | +$596 | ﹤0.01% | 7370 |
|
|
2018
Q4 | $3K | Buy |
6,200
+2,400
| +63% | +$1.3K | ﹤0.01% | 7751 |
|
|
2018
Q3 | $2K | Sell |
3,800
-6,802
| -64% | -$4.13K | ﹤0.01% | 7768 |
|
|
2018
Q2 | $9K | Buy |
+10,602
| New | +$10.4K | ﹤0.01% | 7215 |
|
Other funds holding NVNOW
UBS Group's NVNOW Position: Q1 2023 in Review
UBS Group sold out of enVVeno Medical Corporation Warrants (NVNOW) in Q1 2023, closing a stake of 4,275 shares — an estimated $86 sold.
UBS Group first reported a position in NVNOW in Q2 2018 and held it in 18 quarters. The position peaked at $28K in Q4 2020. 1 fund tracked by Wall St. Rank holds NVNOW as of Q1 2023.
- UBS Group reported no remaining enVVeno Medical Corporation Warrants position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 4,275 enVVeno Medical Corporation Warrants shares in Q1 2023, an estimated $86.
- UBS Group first reported a position in enVVeno Medical Corporation Warrants in Q2 2018 and held it in 18 quarters.
- UBS Group's enVVeno Medical Corporation Warrants position peaked at $28K in Q4 2020.
- 1 fund tracked by Wall St. Rank held enVVeno Medical Corporation Warrants as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.